SKAMo-1: Characterization of the Upper Layers of Skin

Sponsor
Eclypia (Industry)
Overall Status
Completed
CT.gov ID
NCT06044532
Collaborator
(none)
14
1
1
1.9
7.5

Study Details

Study Description

Brief Summary

Diabetes is a frequent disease characterized by chronic hyperglycemia, and its prevalence is increasing worldwide. Historically, patients with diabetes were required to monitor capillary blood glucose concentration up to several times a day through fingertip sampling.

Recently marketed devices now allow measurements of interstitial fluid blood glucose continuously, thus limiting pain associated with sampling. However, they are still invasive and have to be changed every 14 days.

Therefore, to optimize continuous glycemia monitoring while avoiding pain, discomfort, and the risk of infection, non-invasive methods are needed. Among the different strategies being developed, optical wearable sensors with specific signal processing are a promising option. The sensors detecting this optical signal will be included in a device. Yet, wearing a device may slightly modify several properties of the skin, such as its humidity and thermal regulation, and subsequently have an impact on the measured optical signal. Therefore, it is important to better understand how a device affects these characteristics to include these parameters in the future device algorithms.

Condition or Disease Intervention/Treatment Phase
  • Other: Experimental
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
SKAMo-1: Characterization of the Upper Layers of Skin
Actual Study Start Date :
Mar 1, 2023
Actual Primary Completion Date :
Apr 27, 2023
Actual Study Completion Date :
Apr 27, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Skin characterization

Other: Experimental
At the first visit, effects of skin preparations (cleaning or sanding) on skin parameters and wearing a sham device will be evaluated. At the second visit the effect on skin parameters of a local heating and an OGTT will be evaluated.

Outcome Measures

Primary Outcome Measures

  1. Change of skin hydration on the dorsum of the forearm after two and a half hours of wearing the sham device. [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    Hydration is measured with a capacitance method, expressed as arbitrary units (dielectric value)

Secondary Outcome Measures

  1. Change of skin elasticity after the wearing the sham device [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    elasticity (suction method) expressed as penetration depth in mm/time

  2. Change of transepidermal water loss after the wearing the sham device [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    transepidermal water loss (the density gradient of the water evaporation) expressed as the evaporation rate in g/h/m2

  3. Change of thickness of the stratum corneum after the wearing the sham device [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    thickness of the stratum corneum (LC-OCT method) expressed as mm

  4. Change of skin temperature after the wearing the sham device [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    skin temperature (infrared thermography) expressed as Celsius,

  5. Change of skin blood flux after the wearing the sham device [Visit 1,Day 0, before and after two and a half hours of wearing the sham device]

    skin blood flux (LSCI) expressed as an arbitrary unit,

  6. Change of skin hydration after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  7. Change of skin elasticity after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  8. Change of transepidermal water loss after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  9. Change of thickness of the stratum corneum after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  10. Change of skin temperature after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  11. Change of skin blood flux after skin cleaning [Visit 1, Day 0, in 30 minutes, measures taken before and after skin cleaning]

    expressed as previously described

  12. Change of skin hydration after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  13. Change of skin elasticity after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  14. Change of transepidermal water loss after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  15. Change of thickness of the stratum corneum after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  16. Change of skin temperature after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  17. Change of skin blood flux after skin sanding [Visit 1, Day 0, in 30 minutes, measures taken before and after skin sanding]

    expressed as previously described

  18. Change of skin hydration after local heating [Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  19. Change of skin elasticity after local heating [Visit 2, Day 7 (+/-6 days), before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  20. Change of transepidermal water loss after local heating [Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  21. Change of thickness of the stratum corneum after local heating [Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  22. Change of skin temperature after local heating [Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  23. Change of skin blood flux after local heating [Visit 2, Day 7 (+/-6 days) before and after local heating (40 minutes local thermal heating between 33 to 43°C with probes PF457)]

    expressed as previously described

  24. Change of skin hydration induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

  25. Change of skin elasticity induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

  26. Change of transepidermal water loss induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

  27. Change of thickness of the stratum corneum induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

  28. Change of skin temperature induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

  29. Change of skin blood flux induced by oral glycemia tolerance test [Visit 2, Day 7 (+/-6 days), before and during oral glycemia tolerance test (every 15 minutes for 2 hours)]

    expressed as previously described

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or female aged ≥ 18 years and ≤ 60 years

  • Signed informed consent

  • Person who is affiliated to a social security scheme or who is beneficiary of such a scheme

Exclusion Criteria:
  • Body mass index (BMI) > 30 kg/m2

  • Any acute or chronic disease with vascular impact

  • Any cutaneous disease on sites implicated in the study (dorsum of the forearm)

  • Allergy to one of the material used in the sham device and during the procedure of the study

  • The persons mentioned in articles L1121-5 to L1121-8 of the public health code may not be included in this research

  • Subject who would receive more than 4500 euros in compensation due to his or her participation in other research involving the human person in the 12 months preceding this study

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Grenoble Alpes Grenoble France 38043

Sponsors and Collaborators

  • Eclypia

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Eclypia
ClinicalTrials.gov Identifier:
NCT06044532
Other Study ID Numbers:
  • 2022-A02578-35
First Posted:
Sep 21, 2023
Last Update Posted:
Sep 21, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Sep 21, 2023